Vés al contingut

Anna Meseguer Navarro

Institucions de les que formen part

Cap de grup
Fisiopatologia renal
Vall Hebron Institut de Recerca

Anna Meseguer Navarro

Institucions de les que formen part

Cap de grup
Fisiopatologia renal
Vall Hebron Institut de Recerca

Línies de recerca

Role of HAVRC/KIM-1 in the development and progression of the renal clear cell carcinoma (ccRCC) and in the damage/regeneration renal tubular processes

Overexpression of this protein in 60% of the ccRCCs has already been described. HAVR/KIM-1 overexpression in human ccRCC cell lines blocks cell differentiation and promotes cell scattering. We aim to determine the role of HAVR/KIM-1 in the development and progression of ccRCC, and its possible value as a diagnostic and prognostic biomarker. We also focus on KIM-1’s role in ischemia/reperfusion- or nephrotoxic-induced renal tubular injury. Overexpression of this protein in kidney injury has been described. However, whether its involvement is associated with processes enabling to recover tubular epithelium or potentially increasing damage is not known to this date. With the assistance of cultured renal tubular cell models, we are now investigating whether KIM-1 expression shifts are correlated with renal proximal tubule regeneration ability and, as a consequence, investigating its potential therapeutic application.

IP: Anna Meseguer Navarro

Androgen activity in renal pathophysiology: Identification of androgen-regulated kidney-specific genes and functional characterization of them, in processes of inflammation, oxidative stress and fibrosis underlying chronic kidney disease, hypertension and metabolic syndrome.

Among the genes identified in our laboratory that are kidney-specific and regulated by androgens at the transcriptional level we are particularly focused on the one that codes for the kidney androgen-regulated protein (KAP). Besides characterization of  the functional promoter elements that enable KAP expression in proximal tubule epithelial cells, we have generated a transgenic (Tg) mouse model that overexpresses KAP in proximal tubule cells under the presence of androgens, in order to mimick the endogenous KAP expression pattern. KAP Tg mice show altered lipid metabolism, glycosuria, proteinuria and hypertension, as well as focal segmental glomerulosclerosis mediated by increased oxidative stress. We are currently working in this Tg model and also preparing conditional knock-out mice to further caharacterize the role of KAP in renal pathophysiology. Moreover, we are also studying the role of KAP in the metabolic syndrome. Besides KAP, we are studying the role of KAP-interacting immunophilins  in inflammation and kidney fibrosis.

IP: Anna Meseguer Navarro

Rare inhirited renal diseases

Our group is focused in research in primary or inherited tubular renal diseases, such as Dent’s Disease, Bartter syndrome, Tubular Acidosis, Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, among others. Currently we are collaborating  with other groups in Spain, within a research project named Renaltube the main purpose of which is to build a database while facilitating access to genotyping in order to improve the clinical and molecular knowledge of primary tubulopathies. Renaltube has a web-based approach with multilateral collaboration scheme that enhances the recruitment of data and promotes the understanding of underlying mechanisms of rare inherited diseases, defines more accurate diagnostic and follow-up criteria, develops new molecular techniques and will improve the overall care of the patients. Currently we are offering the analysis of 22 genes corresponding to 23 primary tubulopathies. After two years of activity Renaltube has collected data from 222 patients, the mayority from Spain and Latin America (85.3%). The most common tubulopathies are distal renal tubular acidosis (22.5%), and classical Bartter syndrome (19.3%) followed by familial hypomagesemia with hipercalciuria and nephrocalcinosis (15.7%), and Gitelman syndrome (15%).

IP: Gema Ariceta Iraola, Anna Meseguer Navarro

Projectes

KOMPARTE: Sistema digital, multiprofesional, multiplataforma para el registro y explotación de datos del Hospital Universitario Vall d´Hebron.

IP: Alberto Sandiumenge Camps
Col·laboradors: Anna Meseguer Navarro
Entitat finançadora: Diario Médico - Unidad Editorial
Finançament: 0.01
Referència: DM/ENNOVAHEALTH/2022/SANDIUMENGE
Durada: 25/10/2022 - 25/10/2022

NA

IP: Anna Meseguer Navarro
Col·laboradors: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Mónica Durán Fernández, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez , Julieta Torchia
Entitat finançadora: AGAUR no fer servir-correcte 4301-37
Finançament: 40000
Referència: 2021 SGR 01600
Durada: 01/01/2022 - 31/12/2024

Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la enfermedad de Dent 1

IP: Gerard Cantero Recasens
Col·laboradors: Anna Meseguer Navarro, Hector Rios Duro, Mónica Durán Fernández, Gloria Mª Fraga Rodriguez , Julieta Torchia
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 123420
Referència: PI22/00741
Durada: 01/01/2023 - 31/12/2025

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASONIDOS DE INVESTIGACION PRECLINICA

IP: Inmaculada Fuentes Camps
Col·laboradors: Diego Arango Corro, Anna Meseguer Navarro, Antonio Rodríguez Sinovas, Francesc Bosch Albareda, Victor Franco Puntes, José Raul Herance Camacho, Jordi Giralt López de Sagred, Màrius Aguirre Canyadell, Xavier Serres Créixams, Simon Schwartz Navarro, Joaquim Mateo Valderrama, Mario Marotta Baleriola, Anna Rosell Novel, Joan Genescà Ferrer
Entitat finançadora: Ministerio de Ciencia e Innovación-MICINN
Finançament: 108390
Referència: EQC2019-006322-P
Durada: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

Notícies relacionades

Durant dos dies experts han presentat els últims avanços en vectors, les diferents tècniques de modificació de gens i la transferència a la pràctica clínica.

Les principals línies de recerca en aquest camps al VHIR s’han centrat en les immunodeficiències primàries i les malalties autoimmunitàries òrgan-específiques i, progressivament, es van ampliant a altres patologies.

Vall d'Hebron és un referent tant en l'àmbit assistencial, amb més de 30.000 pacients de malalties minoritàries atesos, com en recerca: som el centre de l'Estat amb major nombre d'assajos clínics de malalties minoritàries autoritzats, amb 275 el 2022.

Professionals relacionats

Eva Polverino

Eva Polverino

Investigador/a principal
Pneumologia
Llegir més
Estefania Montiel

Estefania Montiel

Investigador/a principal
Recerca en ictus
Llegir més
Danila Guagnozzi

Danila Guagnozzi

Investigador/a principal
Fisiologia i fisiopatologia digestiva
Llegir més
Baye Elimane Thiaw

Baye Elimane Thiaw

Personal de manteniment i serveis generals
Malalties infeccioses
Llegir més

Subscriu-te als nostres butlletins i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.